Vale Biolabs receives €164K from Venture Kick to advance brain disease research

Biotech startup Vale Biolabs has received €164,000 (CHF 150,000) from Venture Kick to advance its platform for studying brain diseases and evaluating potential treatments. Founded by Ilaria Incaviglia, Angeliki Damilou, Daniel Medina Cano and Theodoulos Rodosthenous, Vale Biolabs combines lab-grown human brain tissue, automation and predictive AI to help researchers better understand how the brain responds to drugs and support the development of new therapies. The founding team brings together expertise in organoid neurobiology, automation, data science engineering and early-stage venture development. Developing treatments for neurological disorders remains challenging, particularly because preclinical research relies heavily on animal testing. Differences between animal and human biology can make it difficult to predict how drugs will perform in patients, contributing to failures during clinical trials, increasing development costs and delaying new therapies. Vale Biolabs aims to addr